| Objective:Through studying redients the ancient prescription HeidiHuang wan in treating chronic renal failure with both spleen and kidney deficiency and dampness and evaluating its economic values, to provide an objective basis for clinical application. Methods:Adopt the method of prospective,randomized,parallel positive drug control and observe 160 cases of theCRF patients, who are randomly divided into 80 cases groups that take HeidiHuang wan,with 80 another casesl groups taking ShenkangNing for 2 months continually in the course of treatment.Statistics from the two groups of treatment costs and WHOQOL-BREF rating scale, quality and value of each function and the quality-adjusted life year will be analyzed to make a contrast in cost-utility. Results:1. Per capita cost is 111.6yuan for the groups taking HeidiHuang wan and the other is 189 yuan and the total cost is 41296.16 yuan and 46319.36 yuan respectively for one course。the quality-adjusted life year (QALY) is 11.3 and 8.5 years respectively. HeidiHuang wan saves 1829.71 yuan for the quality-adjusted life year (QALY), so HeidiHuang wan is more economical and more effective.2 There are no adverse reactions during the treatment. Conclusion: HeidiHuang wan is safe, effective, economical and reasonable in the treatment of CRF, sboth spleen and kidney deficiency and dampnes and is in accordance with principles of drug economics. |
PDF Full Text Request